You are here: Home: Audio Program Guide: BCU 1 | 2005   Go to interview with Michael Baum, MD, ChM Go to interview with Joanne L Blum, MD, PhD Go to interview with John Mackey, MD

To listen to individual tracks now, click the icon. To download tracks to a CD, right-click the icon for your preferred file type. Files are provided in WMA for users with Windows Media Player or MP3 for users with other audio players.

Michael Baum, MD, ChM Emeritus Professor of Surgery and Visiting Professor of Medical Humanities University College London London, United Kingdom Click here to download the entire interview WMA MP3
Track 1	Introduction by Neil Love, MD
Track 2	Clinical implications of 68-month follow-up data from the ATAC trial
Track 3	Relative risk reductions in patients with node-negative versus node-positive disease
Track 4	Impact of all-cause mortality on overall survival in ATAC
Track 5	Increased rates of hysterectomy with tamoxifen compared to anastrozole
Track 6	Reduction in early recurrences with anastrozole compared to tamoxifen
Track 7	Potential benefits of neoadjuvant endocrine therapy
Track 8	Side effects observed in ATAC
Track 9	Anastrozole-related arthralgias
Track 10	Benefit of anastrozole in patients with ER-positive, PR-negative phenotype
Track 11	Switching from tamoxifen to an aromatase inhibitor after two to three years
Track 12	Initiation of an aromatase inhibitor after five years of adjuvant tamoxifen
Track 13	Tailoring breast cancer therapy to vulnerable time points
Track 14	Theoretical rationale for the “carryover effect” of adjuvant hormonal therapy
Track 15	Austrian trial (ABCSG-12) of LHRH agonist with tamoxifen or anastrozole with or without zoledronic acid
Track 16	Nonprotocol use of ovarian ablation and an aromatase inhibitor for premenopausal women with ER-positive, PR-positive disease
Track 17	TARGIT trial of targeted intraoperative radiation therapy
Track 18	Risks and benefits of partial breast irradiation techniques
Joanne L Blum, MD Director, Hereditary Cancer Risk Program and Research Site Leader Baylor-Charles A Sammons Cancer Center Dallas, Texas Click here to download the entire interview
Track 1	Introduction by Dr Love
Track 2	US Oncology adjuvant trial (01062): AC followed by docetaxel with or without capecitabine
Track 3	Tolerability of capecitabine in combination with paclitaxel
Track 4	Combination versus sequential single-agent chemotherapy in the metastatic setting
Track 5	Capecitabine plus trastuzumab as first-line therapy for HER2-positive metastatic disease
Track 6	Poor prognosis of patients with ER-negative, PR-negative, HER2-negative disease
Track 7	Individualizing treatment based on time course and response to other therapies
Track 8	Evolution of clinical research with nanoparticle paclitaxel (ABI-007)
Track 9	Tolerability and efficacy of ABI-007
Track 10	Potential role of ABI-007 in clinical practice
Track 11	Gemcitabine/paclitaxel in patients with metastatic disease
Track 12	Advantage of avoiding premedication with ABI-007
Track 13	Nonprotocol adjuvant chemotherapeutic regimen for patients with node-positive disease
Track 14	Adjuvant taxanes for patients with node-negative disease
Track 15	Up-front adjuvant hormonal therapy for postmenopausal patients
Track 16	Nonprotocol management of premenopausal patients with high-risk ER-positive disease
Track 17	Phase II trial of capecitabine/paclitaxel for patients with metastatic breast cancer
John R Mackey, MD Medical Oncologist, Cross Cancer Institute Associate Professor, Medical and Experimental Oncology University of Alberta Chair, Northern Alberta Breast Cancer Program Canadian Leader, Breast Cancer International Research Group Alberta, Canada Click here to download the entire interview
Track 1	Introduction by Dr Love
Track 2	BCIRG 001: Adjuvant TAC versus FAC for patients with node-positive disease
Track 3	Effect of nodal status on benefit of TAC
Track 4	BCIRG 006: Adjuvant AC followed by docetaxel with or without trastuzumab compared to docetaxel/carboplatin/trastuzumab
Track 5	Cardiac toxicities observed in BCIRG 006
Track 6	Incorporating antiangiogenic agents into the adjuvant setting
Track 7	Evaluating biological signals in preoperative trials of chemotherapy and antiangiogenic agents
Track 8	BCIRG 005: TAC versus AC followed by docetaxel as adjuvant therapy
Track 9	Nonprotocol adjuvant chemotherapy in patients with node-positive disease
Track 10	AC followed by docetaxel versus dose-dense ACT and TAC
Track 11	Clinical applicability of MD Anderson neoadjuvant trastuzumab data
Track 12	Toxicity considerations in the selection of adjuvant hormonal therapy
Track 13	Nonprotocol selection of adjuvant hormonal therapy for postmenopausal women
Track 14	Switching from tamoxifen to an aromatase inhibitor after two to three years
Track 15	Therapeutic decision-making in patients who have completed five years of adjuvant tamoxifen
Track 16	Up-front use of adjuvant anastrozole
Track 17	Aromatase inhibitors after two to three years or five years on tamoxifen
Track 18	Benefits of enrolling patients in clinical trials
Track 19	Introduction to enclosed slide presentation by Dr Love